Novavax’s candidate involves a combination of its coronavirus vaccine and flu vaccine candidates. The coronavirus candidate showed efficacy of more than 90% against mild, moderate, and severe disease.
https://www.fool.com/investing/2021/09/11/heres-where-novavax-may-beat-moderna-and-pfizer/